Trial · NCT06841952
Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia
NCT06841952, Not applicable, Not yet recruiting, The First Affiliated Hospital of Soochow University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia. Trials, record NCT06841952. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06841952
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia
- NCT number
- NCT06841952
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 158 participants, estimated
- Lead sponsor
- The First Affiliated Hospital of Soochow University
- Conditions
- AML, Adult
- Interventions
- ATRA+Venetoclax+Azacitidine, Chemotherapy drug
- First posted
- 2025-02-24
- Last updated
- 2025-02-24
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The overall response rate (ORR) after the second therapy | Efficacy was assessed within 2 weeks after completion of the second course of therapy or within 1 week before the third course of therapy | ORR rate was defifined as patients achieving a CRc or PR |
| Primary | The composite complete remission rate (CRc) after the second therapy | Efficacy was assessed within 2 weeks after completion of the second course of therapy or within 1 week before the third course of therapy | complete response (CR) plus complete response with incomplete blood count recovery (CRi)\] after 2 cycles of treatment. |
| Secondary | Composite complete response (CRc) after the first therapy | Efficacy was assessed within 2 weeks after completion of the first course of induction therapy or within 1 week before the second course of therapy | CRc rate was defifined as patients achieving a CR or CRi |
| Secondary | The overall response rate (ORR) after the first therapy | Efficacy was assessed within 2 weeks after completion of the first course of induction therapy or within 1 week before the second course of therapy | ORR rate was defifined as patients achieving a CRc or PR |
| Secondary | Rate of transfusion independence | Up to 28 days after the start of therapy | Rate of transfusion independence (TI) , including platelet transfusion independence rate and red blood cell transfusion independence rate. |
| Secondary | Overall Survival (OS) | up to 2 years after the date of the last enrolled participants | (OS) refers to the length of time from randomization until the death of the patient from any cause. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06841952
GET https://conductscience.org/api/trials/v1/NCT06841952/registered